EXCUSIVE: BioRestorative Therapies Tells Benzinga Co Announces Final Subject In Its BRTX-100 Phase 2 Clinical Trial Safety Cohort Has Been Dosed
Portfolio Pulse from Benzinga Newsdesk
BioRestorative Therapies has announced that the final subject in its BRTX-100 Phase 2 clinical trial safety cohort has been dosed.
June 12, 2023 | 10:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioRestorative Therapies has dosed the final subject in its BRTX-100 Phase 2 clinical trial safety cohort, marking a milestone in the trial.
The dosing of the final subject in the BRTX-100 Phase 2 clinical trial safety cohort is a significant milestone for BioRestorative Therapies. This progress may positively impact the company's stock price in the short term as it demonstrates the company's commitment to advancing its clinical trials and brings it one step closer to potential FDA approval.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100